Hypertension in metabolic syndrome

Advances in Hypertension Research

Volumn , Issue , 2014, Pages 153-183

  Orellana, Cristóbal ^a   Parra, Felipe ^a   Brito, Roberto ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Endothelial dysfunction; Hypertension; Metabolic syndrome

Indexed keywords

EID: 84947204428     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (198)

1. World Health Organization. Global atlas on cardiovascular disease prevention and control: policies, strategies and interventions. 2011.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-2753.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome among US Adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
4. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl. Health Stat. Report 2009;13:1-7.
5. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and Trens of Metabolic Syndrome in the Adult U.S. Population, 1999-2010. J. Am. Coll. Cardiol. 2013;62: 697-703.
6. Misra A, Khurana L. Obesity and the Metabolic Syndrome in Developing Countries. J. Clin. Endocrinol. Metab. 2008; 93:9-30.
7. Florez H, Silva E, Fernandez V, Ryder E, Sulbaran T, Campos G, Calmon G, Clavel E, Castillo-Florez S, Goldberg R. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res. Clin. Pract. 2005;69:63-77.
8. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM, Franco A, Olaiz G, Rull JA, Sepulveda J. Analysis of the agreement between the World Health Organization criteria and the National Cholesterol Education Program-III definition of the metabolic syndrome: results from a population-based survey. Diabetes Care 2003;26:1635-1660.
9. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res. Clin. Pract. 2003;61:29-37.
10. Ozsahin AK, Gokcel A, Sezgin N, Akbaba M, Guvener N, Ozisik L, Karademir BM. Prevalence of the metabolic syndrome in a Turkish adult population. Diabetes Nutr. Metab. 2004;17:230-234.
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
12. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469-480.
13. Phelan S, Wadden TA, Berkowitz RI, Sarwer DB, Womble LG, Cato RK, and Rothman R. Impact of weight loss on the metabolic syndrome. Int. J. Obes. (Lond) 2007;31:1442-1448.
14. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G. The Metabolic Syndrome and 11-Year Risk of Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005;28:385-390.
15. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis. J. Am. Coll. Cardiol. 2010;56:1113-1132.
16. Akosah KO, McHugh VL, Mathiason MA, Kulkarni A, Barnhart SI. Metabolic syndrome and coronary heart disease equivalent conditions in predicting cardiovascular events in young to middle-aged adults. J. Cardiometab. Syndr. 2006;1:173-177.
17. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-2681.
18. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes. Diabetes Care 2007;30:8-13.
19. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008;371:1927-1935.
20. Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 2007;117:204-210.
21. Cortez-Dias N, Martins SR, Belo A, Fiuza M. Association of metabolic risk factors with uncontrolled hypertension: comparison of the several definitions of metabolic syndrome. J. Hypertens. 2013;31:1991-1997.
22. Luk AO, Ma RC, So W-Y, Yang X-L, Kong AP, Ozaki R, Ko GT, Chow C-C, Cockram CS, Chan JC, Tong PC. The NCEP-ATPIII but not the IDF criteria for the metabolic syndrome identify Type 2 diabetic patients at increased risk of chronic kidney disease. Diabet Med. 2008;25:1419-1425.
23. Mancia G, Bombelli M, Facchetti R, Casati A, Ronchi I, Quarti-Trevano F, Arenare F, Grassi G, Sega R. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events. J. Hypertens. 2010;28:999-1006.
24. Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-1518.
25. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A,Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case control study. Lancet 2004;364:937-952.
26. Antikainen R, Jousilahti P, Tuomilehto J. Systolic blood pressure, isolated systolic hypertension and risk of coronary heart disease, strokes, cardiovascular disease and allcause mortality in the middle-aged population. J. Hypertens. 1998;16:577-583.
27. Shin CY, Yun KE, Park HS. Blood pressure has a greater impact on cardiovascular mortality than other components of metabolic syndrome in Koreans. Atherosclerosis 2009;205:614-619.
28. Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi D, Parodi A, Falqui V, Tomolillo C, Deferrari G, Pontremoli R. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J. Intern. Med. 2005;257:454-460.
29. Engstrom G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgarde F. Inflammationsensitive plasma proteins are associated with future weight gain. Diabetes 2003;52:2097-101.
30. Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN. Extreme insulin resistance of the central adipose depot in vivo. Diabetes 2002;51:755-761.
31. Mauriège P, Marette A, Atgié C, Bouchard C, Thériault G, Bukowiecki LK, Marceau P, Biron S, Nadeau A, Després JP. Regional variation in adipose tissue metabolism of severely obese premenopausal women. J. Lipid. 1995;36:672-684.
32. Wine KL. Free fatty acids and type 2 diabetes mellitus. Am J Med 2003;115:29-36.
33. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G. Mechanisms of hypertension in the cardiometabolic syndrome. J. Hypertens. 2009;27:441-451.
34. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003;112:1796-1808.
35. Bremer AA, Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. J. Obes. 2013;2013:393192.
36. Rajala MW, Scherer PE. Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144:3765-3773.
37. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-350.
38. Lord G. Role of leptin in immunology. Nutr. Rev. 2002;60:33-58.
39. Pajvani UB, Scherer PE. Adiponect systemic contributor to insulin sensitivity. Curr. Diab. Rep. 2003;3:207-213.
40. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384-387.
41. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 2003;52:2346-2352.
42. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 2006;55:928-934.
43. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004;114:752-61.
44. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440:944-948.
45. Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, Rajala MW, Du X, Rollman B, Li W, Hawkins M, Barzilai N, Rhodes CJ, Fantus IG, Brownlee M, Scherer PE. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J. Biol. Chem. 2005;280:4617-26.
46. Coenen KR, Hasty AH. Obesity potentiates development of fatty liver and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-deficient mice. Am. J. Physiol. Endocrinol. Metab. 2007;293:492-499.
47. Holvoet P, Kritchevsky S, Tracy R, Mertens A, Rubin S, Butler J, Goodpaster B, Harris T. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004;53:1068-1073.
48. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007;156:279-284.
49. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, Tambascia M, Bouskela E. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics 2006;61:433-440.
50. Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, Nelson KW, Ballantyne CM. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J. Clin. Endocrinol. Metab. 2004;89:2697-2703.
51. Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA 2006 Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring) 2006;14:2127-2131.
52. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397.
53. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr. Rev. 2008;29:777-822.
54. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J. Clin. Invest. 1995;95:2409-2415.
55. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J. Hypertens. 2004;22:2363-2369.
56. Lembo G, Napoli R, Capaldo B, Rendina V, Iaccarino G, Volpe M, Trimarco B, Saccà L. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J. Clin. Invest. 1992;90:24-29.
57. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002;39:496-501.
58. Marsh AJ, Fontes MA, Killinger S, Pawlak DB, Polson JW, Dampney RA. Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus. Hypertension 2003;42:488-493.
59. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation 2002;106:2533-2536.
60. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr. Res. 1998; 24: 789-96.
61. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am. J. Hypertens. 1994;7:886-893.
62. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006;48:239-245.
63. Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with dietinduced obesity and hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004;287:943-949.
64. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G. The adiposetissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell Biol. 2003;35:807-825.
65. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012;59:1069-1078.
66. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl. Acad. Sci. USA 2003;100:14211-14216.
67. Gao YJ. Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/lipoatrophy-related vascular function. Curr. Pharm. Des. 2007; 13: 2185-2192.
68. Lohn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J. 2002;16:1057-1063.
69. Gao YJ, Lu C, Su LY, Sharma AM, Lee RMKW. Modulation of vascular function by perivascular adipose tissue: The role of endothelium and hydrogen peroxide. Br. J. Pharmacol. 2007;151: 323-331.
70. Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin. Exp. Hypertens. A 1991;13:277-296.
71. Petrasek D, Jensen G, Tuck M, Stern N. In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci. 1992;50:1781-1787.
72. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. Invest. 1994;94:2511-2515.
73. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J. Physiol. Endocrinol. Metab. 2003;285:123-129.
74. Kashyap SR, Roman LJ, Lamont J, Masters BS, Bajaj M, Suraamornkul S, Belfort R, Berria R, Kellogg DL, Liu Y, DeFronzo RA. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J. Clin. Endocrinol. Metab. 2005;90:1100-1105.
75. deJongh RT, Serné EH, IJzerman RG, de Vries G, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004;109:2529-2535.
76. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 2003;278:45021-45026.
77. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T, Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006;47:1108-1116.
78. Margaritis M, Antonopoulos AS, Digby J, Lee R, Reilly S, Coutinho P, Shirodaria C, Sayeed R, Petrou M, De Silva R, Jalilzadeh S, Demosthenous M, Bakogiannis C, Tousoulis D, Stefanadis C, Choudhury RP, Casadei B, Channon KM, Antoniades C. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation 2013; 127: 2209-2221.
79. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, Cardillo C.Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005;112:2986-2992.
80. Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N, Veneziani A, Cardillo C. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 2009; 54:995-1000.
81. Taylor PD, McCarthy AL, Thomas CR, Poston L. Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin induced diabetic rats. Br. J. Pharmacol. 1992;107:393-399.
82. Akbari CM, Saouaf R, Barnhill DF, Newman PA, LoGerfo FW, Veves A. (1998 Oct). Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. J. Vasc. Surg. 1998; 28: 687-94.
83. Beltowski J, Wójcicka G, Jamroz A. Stimulatory effect of leptin on nitric oxide production is impaired in dietary-induced obesity. Obes. Res. 2003;11:1571-1580.
84. Fain JN, Tagele BM, Cheema P, Madan AK, Tichansky DS.Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women. Obesity (Silver Spring) 2010;18:890-896.
85. Ferri C, Bellini C, Desideri G, Baldoncini R, Properzi G, Santucci A, De Mattia G. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp. Clin. Endocrinol. Diabetes 1997;105:38-40.
86. vanHarmelen V, Eriksson A, Aström G, Wåhlén K, Näslund E, Karpe F, Frayn K, Olsson T, Andersson J, Rydén M, Arner P. Vascular peptide endothelin-1 links fat accumulation with alterations of visceral adipocyte lipolysis. Diabetes 2008;57:378-386.
87. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004;43:36-40.
88. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004;53:2060-2066.
89. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 2007;56:728-734.
90. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Görlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2005;25:519-525.
91. Gruson D, Rousseau MF, Ketelslegers JM, Hermans MP. Raised plasma Urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J. Clin. Hypertens. (Greenwich) 2010;12:653-660.
92. Barrette PO, Schwertani AG. A closer look at the role of urotensin II in the metabolic syndrome. Front Endocrinol. (Lausanne) 2012;3:165.
93. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 2003;42:594-599.
94. Félétou M, Vanhoutte PM. EDHF: the complete story. First edition. Boca Raton: Taylor & Francis CRC press; 2006.
95. Quinn MT, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc. Natl. Acad. Sci. USA 1985;82:5949-5953.
96. Beltowski J, Wójcicka G, Jamroz-Wisniewska A. Role of nitric oxide and endotheliumderived hyperpolarizing factor (EDHF) in the regulation of blood pressure by leptin in lean and obese rats. Life Sci. 2006;79:63-71.
97. Beltowski J, Wójcicka G, Jamroz-Wisniewska A, Marciniak A. Resistance to acute NO-mimetic and EDHF-mimetic effects of leptin in the metabolic syndrome. Life Sci. 2009;85:557-567.
98. Zucker LM, Zuker TF. Fatty, a new mutation in the rat. J. Hered. 1961;52:275-278.
99. Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996;271:994-996.
100. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey P, Caskey CJ, Jess JF. Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet. 1996;13:18-19.
101. White DW, Wang DW, Chua SC Jr, Morgenstern JP, Leibel RL, Baumann H, Tartaglia LA. Constitutive and impaired signaling of leptin receptors containing the Gln?Pro extracellular domain fatty mutation. Proc. Natl. Acad. Sci. USA 1997;94:10657-10662.
102. Yamashita T, Murakami T, Lida M, Kuwajima M, Shima K. Leptin receptor of Zucker fatty rat performs reduced signal transduction. Diabetes 1997;46:1077-1080.
103. Bray GA. The Zucker fatty rat: a review. Fed. Proc. 1997;36:148-153.
104. Alonso-Galicia M, Brands MW, Zappe DH, Hall JE. Hypertension in obese Zucker rats: role of angiotensin II and adrenergic activity. Hypertension 1996;28:1047-1054.
105. Mizuno M, Sada T, Kato M, Koike H. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens. Res. 2002;25:271-278.
106. van de Brom CE, Huisman MC, Vlasbom R, Boontje NM, Duijst S, Lubberink M, Molthoff CF, Lammertsma AA, van der Velden J, Boer C, Ouwens DM, Diamant M. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc. Diabetol. 2009;8:39.
107. Sparks JD, Phung TL, Bolognino M, Cianci J, Khurana R, Peterson R G, Sowden MP, Corsetti JP, Sparks CE. Lipoprotein alterations in 10-and 20-week-old Zucker diabetic fatty rats: Hyperinsulinemic versus insulinopenic hyperglycemia. Metabolism 1998;47:1315-1324.
108. Serpillon S, Floyd BC, Gupte RS, George S, Kozicky M, Neito V, Recchia F, Stanley W, Wolin MS, Gupte SA. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am. J. Physiol. Heart Circ. Physiol. 2009;297:153-162.
109. Suzaki Y, Ozawa Y, Kobori, H. Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in zucker diabetic fatty rats. Int. J. Biol. Sci. 2006;1:40-46.
110. Schafer S, Schimidts HL, Bleich M, Busch AE, Linz W. Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br. J. Pharmacol. 2004;143:27-32.
111. Xu KZ, Zhu C, Kim MS, Yamahara J, Li Y. Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity. J. Ethnopharmacol. 2009;22:280-287.
112. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega B, Vala H, Pinto R, Garrido P, Sereno J, Fernandes R, Santos P, Velada I, Melo A, Nunes S, Teixeira F, Reis F. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010;2010:592760.
113. Ernsberger P, Koletsky RJ, Friedman JE. Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of Syndrome X. Ann. NY Acad. Sci. 1999;892:272-288.
114. Hiraoka J, Hosoda K, Ogawa Y, Ikeda K, Nara Y, Masuzaki H, Takaya K, Nakagawa K, Mashimo T, Sawamura M, Koletsky RJ, Yamori Y, Nakao K. Augmentation of obese (ob) gene expression and leptin secretion in obese spontaneously hypertensive rats (Obese SHR or Koletsky rats). Biochem. Biophys. Res. Commum. 1997;231:582-585.
115. Takaya K, Ogawa Y, Hiroaka J, Hosoda K, Yamori Y, Nakao K, Koletsky RJ. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat. Genet. 1996;14:130-131.
116. Alexaindre de Artiñano A, Miguel Castro, M. Experimental rat models to study the metabolic syndrome. Br. J. Nutr. 2009;102:1246-1253.
117. Ernsberger P, Koletsky RJ, Baskin, JS, and Foley, M. Refeeding hypertension in obese spontaneously hypertensive rats. Hypertension 1994;24:699-705.
118. Mendizabal Y, Llorens, S, and Nava, E. Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones. Am. J. Physiol. Heart Circ. Physiol. 2011;301;1319-1330.
119. Shima K, Zhu M, Mizuno A. Pathoetiology and prevention of NIDDM lessons from the OLETF rat. J. Med. Invest. 1999;46:121-129.
120. Antin J, Gibbs J, Holt J, Young RC, Smith, G. P. Cholecystokinin elicits the complete behavioral sequence of satiety in rats. J. Comp. Physiol. Psychol. 1975; 89:784-790.
121. Moran TH, Bi S. Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors. Dev. Psychobiol. 2006;48:360-367.
122. Kawano K, Hirashima T, Mori S, Natori T. OLETF (Otsuka Long-Evans Tokushima fatty) rat: a new NIDDM rat strain. Diabetes Res. Clin. Pract. 1994;24:317-320.
123. Karakikes, I Kim, M, Hadri L, Sakata, Sun Y, Zhang W, Chemaly ER, Hajjar RJ, Lebeche D. Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a. PLoS One 2009;4:6474.
124. Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H.Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fatty rats. Hypertension 1997;29:728-735.
125. Kawano T, Nomura M, Nisikado A, Nakaya Y, Ito S. Supplementation of L-arginine improves hypertension and lipid metabolism but not insulin resistance in diabetic rats. Life Sci. 2003;73:3017-3026.
126. Massiera F, Barbry P, Guesnet P, Joly A, Luguet S, Moreilhon-Brest C, Mohsen-Kanson T, Amri EZ, Ailhaud GA. Western-like fat diet is sufficient to induce a gradual enhancement in fat mass over generations. J. Lipid Res. 2010;51:2352-2361.
127. Le K A, Tappy L. Metabolic effects of fructose. Curr. Opin. Clin. Nutr. Metab. Care 2006;9:469-475.
128. Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 2010;90:23-46.
129. Bray GA, Nielsen S J, Popkin, BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am. J. Clin. Nutr. 2004;79:537-543.
130. Tran LT, Yuen VG, McNeill JH. The fructose fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension. Mol. Cell Biochem. 2009;332:145-159.
131. Patel J, Iyer A, Brown L. Evaluation of the chronic complications of diabetes in a high fructose diet in rats. Indian J. Biochem. Biophys. 2009;46:66-72.
132. Chang KC, Liang Jt, Tseng CD, Wu, ET, Hsu KL, Wu MS, Lin YT, Tseng YZ. Aminoguanidine prevents fructose-induced deterioration in left ventriculararterial coupling in Wistar rats. Br. J. Pharmacol. 2007;151:34-36.
133. Kawasaki T, Igarash, K koeda, T, Sugimoto K, Nakagawa K, Hayashi S, Ymaji R, Iyi, H, Fukusato, T, and Yamanouchi, T. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J. Nutr. 2009;139:2067-2071.
134. Bocarsly ME, Powell ES, Avena, NM, Hoebel, BG. High-fructose corn syrup causes characteristics of obesity in rats: increased body weight, body fat and triglyceride levels. Pharmacol. Biochem. Behav. 2010;97:101-106.
135. Nakayama T, Kosugi T, Gersch M, Connor T, Sanchez-Lozada LG, Lanaspa MA, Roncal C, Perez-Pozo SE, Johnson R J, Nakagawa T. Dietary fructose causes tubulointerstitial injury in the normal rat kidney. Am. J. Physiol. Renal. Physiol. 2010;29:712-720.
136. Miatello R, Vazquez M, Renna, Cruzado M, Zumino, A P, and Risler, N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose fed rats. Am. J. Hypertens. 2005;18:864-870.
137. Panchal SK, Poudyal H, Lyer A, Nazer R, Alam MA, Diwan V, Kauter K, Sernia C, Campbell F, Ward L, Gobe G, Fenning A, Brown L. High carbohydrate high fat dietinduced metabolic syndrome and cardiovascular remodeling in rats. J. Cardiovasc. Pharmacol. 2011;57:611-624.
138. Kanarek R B, Aprille JR, Hirsh E, Gualtiere L, Brown CA. Sucrose-induced obesity: effect of diet on obesity and brown adipose tissue. Am. J. Physiol. 1987;253:158-166.
139. Santure M, Pitre M, Marette A, Deshaies Y, Lemieux C, Lariviere R, Nadeau A, Bachelard H. Induction of insulin resistance by high-sucrose feeding does not raise mean arterial blood pressure but impairs haemodynamic responses to insulin in rats. Br J. Pharmacol. 2002;137:185-196.
140. Coehlo MS, Lope KL, Freitas RA, de Oliveira-Sales EB, Bergasmaschi CT, Campos RR, Casarini DE, Carmona AK, Araujo MS, Heimann JC, Dolnikoff MS. High sucrose intake in rats is associated with increased ACE2 and angiotensin-(1-7) levels in the adipose tissue. Regul. Pept 2010;162:61-67.
141. Lombardo YB, Drago S, Chicco A, Fainstein-Day P, Gutman R, Gagliardino JJ, Gomez Dumm CL. Long-term administration of a sucrose-rich diet to normal rats: Relationship between metabolic and hormonal profiles and morphological changes in the endocrine pancreas. Metabolism 1996;45:1527-1532.
142. Sharma N, Okere IC, Barrows BR, Lei B, Duda MK, Yuan CL, Previs SF, Sharov VG, Azimzadeh AM, Ernsberger P, Hoit BD, Sabbah H, Stanley WC. High-sugar diets increase cardiac dysfunction and mortality in hypertension compared to lowcarbohydrate or high-starch diets. J. Hypertens. 2008;26:1402-1410.
143. Huang W, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, Scott, DK, O'Doherty RM. Depletion of liver kupffer cells prevents the development of dietinduced hepatic steatosis and insulin resistance. Diabetes 2010;59:347-357.
144. Woods SC, Seeley RJ, Rushing PA, D'Alessio D, Tso PA. Controlled high-fat diet induces an obese syndrome in rats. J. Nutr. 2003;133:1081-1087.
145. Kobayasi R, Akamine EH, Davel AP, Rodrigues MA, Carvalho CR, Rossoni LV. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. J. Hypertens. 2010;28:2111-2119.
146. Deji N, Kume S, Araki S, Soumura M, Sugimoto T, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Koya D, Haneda M, Kashiwagi A, Uzu T. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am. J. Physiol. Renal. Physiol. 2009;296:118-126.
147. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Scholmerich J, Bolheimer LC. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J. Mol. Endocrinol. 2006;36:485-501.
148. Sutherland LN, Capozzi LC, Turchinsky NJ, Bell RC, Wright DC. Time course of highfat diet-induced reductions in adipose tissue mitochondrial proteins: potential mechanisms and the relationship to glucose intolerance. Am. J. Physiol. Endocrinol. Metab. 2008;295:1076-1083.
149. Lei F, Zhang XN, Wang W, Xing DM, Xie WD, Su H, Du LJ. Evidence of antiobesity effects of the pomegranate leaf extract in high-fat diet induced obese mice. Int. J. Obes. 2007;31:1023-1029.
150. Sweazea KL, Lekic M, Walker BR. Comparison of mechanisms involved in impaired vascular reactivity between high sucrose and high fat diets in rats. Nutr. Metab. 2010;4:7-48.
151. Kim SM, Rico CW, Lee SC, Kang MY. Modulatory effect of rice bran and phytic acid on glucose metabolism in high fat-fed C57BL/6N mice. J. Clin. Biochem. Nutr. 2010;47:12-17.
152. Hsu CL, Wu CH, Huang SL, Yen GC. Phenolic compounds rutin and o-coumaric acid ameliorate obesity induced by high-fat diet in rats. J. Agric. Food Chem. 2009;57:425-431.
153. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010;52:934-944.
154. Murase T, Mizuno T, Omachi T, Onizawa K, Komine Y, Kondo H, Hase T, Tokimitsu I. Dietary diacylglycerol suppresses high fat and high sucrose diet-induced body fat accumulation in C57BL/6J mice. J. Lipid Res. 2001;42:372-378.
155. Parekh PI, Petro AE, Tiller JM, Feinglos MN, Surwit RS. Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism 1998;47:1089-1096.
156. Sato A, Kawano H, Notsu T, Ohta M, Nakakuki M, Mizuguchi K, Itoh M, Suganami T, Ogawa Y. Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose dietinduced obesity: importance of hepatic lipogenesis. Diabetes 2010;59:2495-2504.
157. Hsu CL, Wu CH, Huang SL, Yen GC. Phenolic compounds rutin and o-coumaric acid ameliorate obesity induced by high-fat diet in rats. J. Agric. Food Chem. 2009;57:425-431.
158. Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, Koya D, Tsuneki H, Sasaoka T. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010;151:2040-9.
159. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW, Rudich S, Weintraub NL. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ. Res. 2009;104:541-549.
160. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 2001;37:554-560.
161. Ketonen J, Shi J, Martonen E, Mervaala E. Periadventitial adipose tissue promotes endothelial dysfunction via oxidative stress in diet-induced obese C57BL/6 mice. Circ. J. 2010;74:1479-1487.
162. Elizalde M, Ryden M, van Harmelen V, Eneroth P, Gyllenhammar H, Holm C, Ramel S, Olund A, Arner P, Anderson K. Expression of nitric oxide synthases in subcutaneous adipose tissue of non obese and obese humans. J. Lipid Res. 2000;41:1244-1251.
163. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog. Cardiovasc. Dis. 1998;41:39-52.
164. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the Carvedilol-Metoprolol study. J. Hypertens. 1996;14:489-494.
165. Lund-Johansen P, Omvik P, Nordrehauq JE. Long-term hemodynamic effects of antihypertensive treatment. Clin. Investig. 1992;70-58-64.
166. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffnes, hypertension, and rational use of nebivolol. Vasc. Health Risk Manag. 2009;5:353-360.
167. DeFronzo RA, Mandarino L, Ferranini E. Metabolic and molecular pathogenesis of type 2 diabetes mellitus. In: DeFronzo RA, Ferrannini E, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus, Vol 1, 3rd ed. Chichester: John Wiley & Sons Ltd; 2004:389-438.
168. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007;67:1097-1107.
169. Louis WJ, McNeill JJ, Drummer OH. Pharmacology of combined alpha-beta-blockade. Drugs 1984;28:16-34.
170. Siwach SB, Dahiya SS, Seth S, Seth RK, Sharma D. Effect of atenolol and labetalol on serum lipids. J. Assoc. Physicians India 1993;41:293-294.
171. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr. Hypertens. Rep. 2007;9:269-277.
172. Kozlovski VI, Lomnicka M, Chlopicki S. Nebivovol and carvedilol induce NOdependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol. Rep. 2006;58:103-110.
173. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J. Hypertens. 2007;25:731-741.
174. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol. Ther. 2003;100:215-234.
175. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, Lo Cascio V, Cominacini L. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J. Hypertens. 2005;23:589-596.
176. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, Elisaf M, Mikhailidis DP. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J. Cardiovasc. Pharmacol. Ther. 2003;8:127-134.
177. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens. 2005;2:463-473.
178. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S; LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens. 2002;20:1879-1886.
179. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19.257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31:982-988.
180. Lardizabal JA, Deedwania PC. The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. Curr. Cardiol. Rep. 2010;12:464-471.
181. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 2003;348:583-592.
182. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G; Scientific Council of the European Society of Hypertension. The metabolic syndrome in hypertension: European Society of Hypertension position statement. J. Hypertens. 2008;26:1891-1900.
183. Grimm C, Köberlein J, Wiosna W, Kresimon J, Kiencke P, Rychlik R. New-onset diabetes and antihypertensive treatment. GMS Health Technol. Assess. 2010;6:3.
184. Flora S. Role of free radicals and antioxidants in health and disease. Cell. Mol. Biol. 2007:53:1-2.
185. Zhan CD, Sindhu RK, Vaziri ND. Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: reversal by lifelong antioxidant supplementation. Kidney Int. 2004;65:219-227.
186. Antoniades C, Tousoulis D, Tentolouris C, Toutouzas P, Stefanadis C. Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice. Herz 2003;28:628-638.
187. Duarte TL, Lunec J. Review: when is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C. Free Radic. Res. 2005;39:671-686.
188. Ulker S, McKeown PP, Bayraktutan U. Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities. Hypertension 2003;41:534-549.
189. Faure P, Barclay D, Joyeux-Faure M, Halimi S. Comparison of the effects of zinc alone and zinc associated with selenium and vitamin E on insulin sensitivity and oxidative stress in high-fructose-fed rats. J. Trace Elem. Med. Biol. 2007;21:113-119.
190. Moreau KL, Gavin KM, Plum AE, Seals DR. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women. Hypertension 2005;45:1107-1112.
191. Schneider MP, Delles C, Schmidt BM, Oehmer S, Schwarz TK, Schmieder RE, John S. Superoxide scavenging effects of N-acetylcysteine and vitamin C in subjects with essential hypertension. Am. J. Hypertens. 2005;18:1111-1117.
192. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001;103:1618-1623.
193. Shimamoto K, Ura N. Mechanisms of insulin resistance in hypertensive rats. Clin. Exp. Hypertens. 2006;28:543-552.
194. Quinzii CM, López LC, Naini A, DiMauro S, Hirano M. Human CoQ10 deficiencies. Biofactors 2008;32:113-118.
195. Lankin VZ, Tikhaze AK, Kapel'ko VI, Shepel'kova GS, Shumaev KB, Panasenko OM, Konovalova GG, Belenkov YN. Mechanisms of oxidative modification of low density lipoproteins under conditions of oxidative and carbonyl stress. Biochemistry (Mosc) 2007;72:1081-1090.
196. Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, Zhang C. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ. Res. 2006;99:69-77.
197. Ginsberg HN. Insulin resistance and cardiovascular disease. J. Clin. Invest. 2000;106:629-631.
198. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol. 2004;24:816-823.